NCT03700515

Exosome Proteomics to Detect EPO

Exosome Proteomics to Detect Eyrthropoietin (EPO) Use in Athletes

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Morten Hostrup, PhD · Academic / Other
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The role of exosomes in cell signalling has only recently been appreciated and is a hugely exciting and rapidly growing area, and combined with LC-MS/MS proteomics, can overcome traditional barriers to proteomics in doping applications. To our knowledge, no research has yet been undertaken to explore whether the highly promising combination of exosome proteomics has utility for rhEPO detection. The applications are extensive; the diagnostic value of differentially regulated proteins could be further validated against the existing IEF EPO WADA accredited tests using samples collected during this study, used to study altitude hypoxia versus exogenous EPO administration (WADA current targeted research 2017), investigated as a platform approach to ESA and HIF agents more generally, as well as facilitate development of direct ELISA high throughput tests.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Erythropoietin	Subjects receive weekly infusions of EPO
DRUG	Placebo	Subjects receive weekly infusions of saline

Timeline

• Start date: 2019-09-04
• Primary completion: 2020-10-15
• Completion: 2020-10-15
• First posted: 2018-10-09
• Last updated: 2019-09-25

Locations

1 site across 1 country: Denmark